Literature DB >> 2742439

Intermittent compression units for the postphlebitic syndrome. A pilot study.

J S Ginsberg1, P Brill-Edwards, G Kowalchuk, J Hirsh.   

Abstract

The postphlebitic syndrome is a common affliction with limited therapeutic options. Patients who fail to respond to treatment with graded elastic compression stockings often develop a chronic pain syndrome manifested by intractable pain and swelling. Because lymphedema, a condition also associated with leg pain and swelling, has been successfully treated by intermittent compressive therapy with an extremity pump, we conducted a pilot study of compressive therapy in patients with severe postphlebitic syndrome. All five patients studied had dramatic improvement in symptoms and functional status without side effects. Although a large randomized trial is needed to properly evaluate compressive therapy, it appears to be very effective in selected patients.

Entities:  

Mesh:

Year:  1989        PMID: 2742439

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

Review 1.  The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis.

Authors:  Susan R Kahn
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

Review 2.  [S1 guideline on intermittent pneumatic compression (IPC)].

Authors:  C Schwahn-Schreiber; F X Breu; E Rabe; I Buschmann; W Döller; G R Lulay; A Miller; E Valesky; S Reich-Schupke
Journal:  Hautarzt       Date:  2018-08       Impact factor: 0.751

3.  Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study.

Authors:  J S Ginsberg; D Magier; B Mackinnon; M Gent; J Hirsh
Journal:  CMAJ       Date:  1999-05-04       Impact factor: 8.262

Review 4.  Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life.

Authors:  S R Kahn; S Solymoss; D L Lamping; L Abenhaim
Journal:  J Gen Intern Med       Date:  2000-06       Impact factor: 5.128

5.  Effectiveness of compression stockings to prevent the post-thrombotic syndrome (the SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial.

Authors:  Susan R Kahn; Hadia Shbaklo; Stan Shapiro; Philip S Wells; Michael J Kovacs; Marc A Rodger; David R Anderson; Jeffrey S Ginsberg; Mira Johri; Vicky Tagalakis
Journal:  BMC Cardiovasc Disord       Date:  2007-07-24       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.